

Receipt of First Tranche of \$1.69m in Research & Development Tax Incentive

Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: **RHY**) (**Rhythm** or the **Company**), is pleased to advise that it has received the first tranche of its research and development (R&D) tax incentive totalling \$1.69 million. This forms part of the Australian government's R&D tax incentive program.

This initial receipt of the R&D tax incentive recognises the Australian based activities undertaken by Rhythm during the financial year ended 30 June 2023. The receipt of the \$1.69 million, is expected to be complemented by a further receipt for research and development activities undertaken overseas.

The second receipt is expected in 2024, once verified and lodged by the Company's tax advisers.

- ENDS -

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investor@rhythmbio.com or on +61 3 8256 2880:

| | | |
|---|--|--|
| Mr. Otto Buttula Executive Chairman | Mr. Paul Smith CFO & Joint Company Secretary | Mr. Guy Carisbrooke Financial Controller |
|---|--|--|

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and Twitter.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT® Test-Kit is Rhythm Bioscience's simple blood test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood presence of CRC. The test can be used as an alternative for individuals who are unable or unwilling to participate in current screening programs.

The ColoSTAT® Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

Rhythm Biosciences Ltd
ACN 619 459 335
ASX: RHY

www.rhythmbio.com

Australian Registered Address

Bio21 Molecular Science & Biotechnology Institute
30 Flemington Road
Parkville VIC 3010 Australia

T +61 3 8256 2880
E info@rhythmbio.com

Directors

Otto Buttula
Sue MacLeman
Trevor Lockett
Rachel David
Louis Panaccio

Executive Chairman
Independent Deputy Chair
Executive Director
Non-Executive Director
Non-Executive Director